company background image

TherapeuticsMD NasdaqGS:TXMD Stock Report

Last Price


Market Cap







26 Jun, 2022


Company Financials +
TXMD fundamental analysis
Snowflake Score
Future Growth1/6
Past Performance0/6
Financial Health0/6

TXMD Stock Overview

TherapeuticsMD, Inc. operates as a women’s healthcare company in the United States.

TherapeuticsMD Competitors













Price History & Performance

Summary of all time highs, changes and price drops for TherapeuticsMD
Historical stock prices
Current Share PriceUS$9.90
52 Week HighUS$62.50
52 Week LowUS$1.99
1 Month Change378.26%
3 Month Change-50.56%
1 Year Change-83.50%
3 Year Change-92.38%
5 Year Change-96.24%
Change since IPO-80.20%

Recent News & Updates

Jun 16

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

TherapeuticsMD’s $177 million buyout deal with EW Healthcare largely undervalues the biotech. TherapeuticsMD is close to stimulating the commercialization of Annovera which may increase its value as a standalone company in the long run. Shareholders were informed of a 50:1 reverse stock split at the end of Q1 2021 just a few days before the buyout was announced. Investors are in support of the acquisition due to TherapeuticsMD's poor financial position but insist on better terms including an expanded bidding process.

Shareholder Returns

TXMDUS PharmaceuticalsUS Market

Return vs Industry: TXMD underperformed the US Pharmaceuticals industry which returned 12.5% over the past year.

Return vs Market: TXMD underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is TXMD's price volatile compared to industry and market?
TXMD volatility
TXMD Average Weekly Movement106.9%
Pharmaceuticals Industry Average Movement11.6%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: TXMD is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 48% a day.

Volatility Over Time: TXMD's weekly volatility has increased from 54% to 107% over the past year.

About the Company

2008416Hugh O’Dowd

TherapeuticsMD, Inc. operates as a women’s healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation.

TherapeuticsMD Fundamentals Summary

How do TherapeuticsMD's earnings and revenue compare to its market cap?
TXMD fundamental statistics
Market CapUS$87.58m
Earnings (TTM)-US$182.05m
Revenue (TTM)US$86.42m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TXMD income statement (TTM)
Cost of RevenueUS$19.01m
Gross ProfitUS$67.41m
Other ExpensesUS$249.46m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-20.58
Gross Margin78.00%
Net Profit Margin-210.67%
Debt/Equity Ratio-144.3%

How did TXMD perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is TXMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TXMD?

Other financial metrics that can be useful for relative valuation.

TXMD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.1x
Enterprise Value/EBITDA-2.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does TXMD's PS Ratio compare to its peers?

TXMD PS Ratio vs Peers
The above table shows the PS ratio for TXMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.8x

Price-To-Sales vs Peers: TXMD is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (1.8x).

Price to Earnings Ratio vs Industry

How does TXMD's PE Ratio compare vs other companies in the U.S. Pharmaceuticals Industry?

Price-To-Sales vs Industry: TXMD is good value based on its Price-To-Sales Ratio (1x) compared to the US Pharmaceuticals industry average (3.9x)

Price to Sales Ratio vs Fair Ratio

What is TXMD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TXMD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ratio717.6x

Price-To-Sales vs Fair Ratio: TXMD is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (717.6x).

Share Price vs Fair Value

What is the Fair Price of TXMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TXMD ($9.9) is trading below our estimate of fair value ($81.58)

Significantly Below Fair Value: TXMD is trading below fair value by more than 20%.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TXMD's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is TherapeuticsMD forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score


Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TXMD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TXMD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TXMD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TXMD's revenue (20% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: TXMD's revenue (20% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TXMD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has TherapeuticsMD performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TXMD is currently unprofitable.

Growing Profit Margin: TXMD is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: TXMD is unprofitable, and losses have increased over the past 5 years at a rate of 16.3% per year.

Accelerating Growth: Unable to compare TXMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TXMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.7%).

Return on Equity

High ROE: TXMD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Discover strong past performing companies

Financial Health

How is TherapeuticsMD's financial position?

Financial Health Score


Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TXMD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: TXMD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.

Debt to Equity History and Analysis

Debt Level: TXMD has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: TXMD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TXMD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TXMD has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.4% each year

Discover healthy companies


What is TherapeuticsMD current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate TXMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TXMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TXMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TXMD's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TXMD has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Hugh O’Dowd (55 yo)





Mr. Hugh O’Dowd, M.B.A., serves as President at TherapeuticsMD, Inc. since August 30, 2021 and serves as its Chief Executive Officer since December 14, 2021 and also serves as its Director since December 1...

CEO Compensation Analysis

Compensation vs Market: Hugh's total compensation ($USD5.57M) is above average for companies of similar size in the US market ($USD752.25K).

Compensation vs Earnings: Insufficient data to compare Hugh's compensation with company performance.

Leadership Team

Experienced Management: TXMD's management team is seasoned and experienced (6.3 years average tenure).

Board Members

Experienced Board: TXMD's board of directors are considered experienced (4.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.

Top Shareholders

Company Information

TherapeuticsMD, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: TherapeuticsMD, Inc.
  • Ticker: TXMD
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$87.583m
  • Shares outstanding: 8.85m
  • Website:

Number of Employees


  • TherapeuticsMD, Inc.
  • 951 Yamato Road
  • Suite 220
  • Boca Raton
  • Florida
  • 33431
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.